PharmaVentures Podcast Series, Edition 4 

 


Robust Valuations of Life Science Companies, Assets and Licensing Deals

 

Hosted by Adrian Dawkes

Listen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience is combined with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals to give their clients the confidence to negotiate the most robust and defensible positions in deal making to secure the most impactful financial terms.

Podcast: Robust Valuations of Life Science Companies, Assets and Licensing Deals

Download Request

If you would prefer to read the transcript of the podcast please email: enquiries@pharmaventures.com

 

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

 

About the Interviewees:

Stephen Waterman is a Managing Director at PharmaVentures.

He joined PharmaVentures in 2012, after a long career in Healthcare Investment Banking. At PharmaVentures, Stephen has originated and worked on a number of strategic advisory, licensing and M&A mandates, assisting his clients find the optimal solutions to their challenges and opportunities.

Kyriakos Tzafestas is a Director at PharmaVentures.

Prior to joining PharmaVentures, Kyriakos was a life sciences consultant working with biotech companies and early-stage technologies on projects encompassing market analysis, competitive intelligence, opportunity assessment, commercialisation roadmaps, patent landscaping, valuations, and business development for research collaborations and licensing opportunities. Before commencing his professional career, Kyriakos completed a Master of Biotechnology (Distinction) at the University of Glasgow and obtained a PhD in Molecular Biology from the University of York.